Xcout Intel
BridgeBio Pharma, Inc. competitors & alternatives
The 12 closest competitors and alternatives to BridgeBio Pharma, Inc. among biopharmaceuticals companies — ranked by similarity to what BridgeBio Pharma, Inc. actually does, not by market-cap band.
Subscribe to see BridgeBio Pharma, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
BridgeBio Pharma, Inc. at a glance
BridgeBio Pharma, Inc. is a biopharmaceuticals company headquartered in Palo Alto, United States, founded in 2015. It is publicly listed (BBIO) with a market capitalisation of $12.8B. Xcout tracks 24 named people at BridgeBio Pharma, Inc., including Eric Michael David (Chief Executive Officer of Gene Therapy).
BridgeBio Pharma, Inc. leadership
- Eric Michael DavidChief Executive Officer of Gene Therapy
- Thomas TrimarchiChief Financial Officer & President
- Uma SinhaChief Scientific Officer
- Eli WallaceChief Scientific Officer of Oncology
- Maricel ApuliChief Accounting Officer
- Matthew OuttenChief Commercial Officer
18 more named people on record for BridgeBio Pharma, Inc., with roles, board committees and tenure — see the full roster →
Hiring at BridgeBio Pharma, Inc.
Tools named in BridgeBio Pharma, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see BridgeBio Pharma, Inc.'s hiring signals →
Top 12 BridgeBio Pharma, Inc. competitors
Ranked by semantic similarity — how close each company is to BridgeBio Pharma, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Drug Discovery
Bridge Medicines LLC is a drug discovery holding company headquartered in New York, NY, that accelerates the path of therapeutic pipelines from research to patients.
Drug Development
Bend Bioscience is a U.S. pharmaceutical contract development and manufacturing organization (CDMO) dedicated to advancing pharmaceutical innovation. It offers design, development, and manufacturing services ranging from early formulation to commercial-scale production.
Similar biopharmaceuticals company
Avidity Biosciences, Inc. is a biopharmaceutical company dedicated to delivering a novel class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs) to profoundly improve people's lives. Headquartered in San Diego, California, the firm focuses on advancing precision genetic medicines for various diseases. As of February 2026, the company operates as a subsidiary of Novartis.
Drug Discovery
Enlaza Therapeutics, Inc. is a biotechnology enterprise headquartered in California, United States. The company designs and develops next-generation covalent biologic therapeutics targeting serious diseases. It utilizes specialized proprietary discovery platforms to advance precision medicine applications.
Similar biopharmaceuticals company
Allena Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Newton, Massachusetts, focused on the research, development, and commercialization of orally administered enzyme therapeutics for rare and severe metabolic and kidney disorders.
Drug Discovery
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Drug Discovery
Lighthouse Pharma is a clinical-stage private biopharmaceutical company that specializes in precision medicine approaches targeting major unmet medical needs. The company is headquartered at the Buck Institute for Research on Aging in California.
Similar biopharmaceuticals company
Amicus Therapeutics, Inc. is an American biopharmaceutical company based in Princeton, New Jersey, dedicated to advancing therapies to treat rare diseases.
Similar biopharmaceuticals company
Cydan is a biotechnology company builder and accelerator focused on creating and financing companies that develop treatments for rare diseases. It works with researchers, entrepreneurs, and investors to advance therapeutic programs toward clinical development.
Similar biopharmaceuticals company
ChemoCentryx, Inc. is a biopharmaceutical company with its corporate headquarters and principal place of business located in California.
Similar biopharmaceuticals company
Mendra is a venture-backed biotechnology research startup established in 2025 and headquartered in San Francisco, focused on accelerating the development and commercialization of rare disease therapies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of BridgeBio Pharma, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for BridgeBio Pharma, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →